it’s only 13% of the DMD population.
And don’t forget
Sareptas drugs can’t get passed in Europe
Atl1102 can reduce inflammation and so can work in combination with all of Sareptas drugs ….
anyway
Yet to be passed by the FDA
and because of the costs Insurance reimbursement may not apply …
Sarepta is yet to make a profit
thus
pursuing a bigger slice of the DMD population…
Still yet to show efficacy
Let’s go, page-90
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
